Critical Comparison: Centogene (CNTG) vs. Its Rivals
Centogene (NASDAQ: CNTG) is one of 29 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Centogene to related companies based on the strength of its dividends, risk, valuation, institutional ownership, analyst recommendations, earnings and profitability.
Earnings and Valuation
This table compares Centogene and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Centogene||$54.64 million||-$23.36 million||-12.52|
|Centogene Competitors||$985.62 million||$50.20 million||33.70|
Insider & Institutional Ownership
8.3% of Centogene shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 13.4% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Centogene and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for Centogene and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Centogene currently has a consensus target price of $21.50, suggesting a potential upside of 17.61%. As a group, “Medical laboratories” companies have a potential upside of 25.24%. Given Centogene’s competitors higher possible upside, analysts clearly believe Centogene has less favorable growth aspects than its competitors.
Centogene competitors beat Centogene on 7 of the 12 factors compared.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.